Who are Midodrine + pyridostigmine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/midodrine-pyridostigmine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Midodrine + pyridostigmine — Competitive Intelligence Brief

Midodrine + pyridostigmine (Midodrine + pyridostigmine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-1 adrenergic agonist + acetylcholinesterase inhibitor combination. Area: Cardiovascular.

marketed Alpha-1 adrenergic agonist + acetylcholinesterase inhibitor combination Alpha-1 adrenergic receptor; acetylcholinesterase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Midodrine + pyridostigmine (Midodrine + pyridostigmine) — Seoul National University Hospital. Midodrine and pyridostigmine together increase blood pressure and improve symptoms of orthostatic hypotension by enhancing sympathetic activation and acetylcholine availability.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Midodrine + pyridostigmine TARGET	Midodrine + pyridostigmine	Seoul National University Hospital	marketed	Alpha-1 adrenergic agonist + acetylcholinesterase inhibitor combination	Alpha-1 adrenergic receptor; acetylcholinesterase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-1 adrenergic agonist + acetylcholinesterase inhibitor combination class)

Seoul National University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Midodrine + pyridostigmine — Competitive Intelligence Brief. https://druglandscape.com/ci/midodrine-pyridostigmine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab